B of A Securities Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $65
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Greg Harrison has initiated coverage on Keros Therapeutics (NASDAQ:KROS) with a Buy rating and a price target of $65.
July 26, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keros Therapeutics has been initiated with a Buy rating by B of A Securities, with a price target of $65.
The initiation of coverage by B of A Securities with a Buy rating and a price target of $65 indicates a positive outlook for Keros Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100